May 1, 2020
RegMed Investors (RMi): April - a roller coaster month ends
April 11, 2020
Regenerative Medicine Earnings Scorecard - Q4 & FY19
April 10, 2020
Sangamo Therapeutics (SGMO) closed its Biogen (BIIB) collaboration agreement
April 7, 2020
Sage Therapeutics (SAGE) Restructuring
March 30, 2020
Athersys (ATHX); HEALIOS K.K., its partner in Japan exercised in full its 4 million warrants to purchase shares at $1.76
March 29, 2020
RegMed Investors’ (RMi): the coming week ...
March 16, 2020
Applied Genetic Technologies Corporation (AGTC) has completed the planned enrollment
March 6, 2020
BrainStorm Cell Therapeutics (BCLI) $10 M registered direct offering (RDO) priced at $8.00
February 28, 2020
Verastem (VSTM) offers 46.5 M private placement priced at $2.15 valued at $100 M to institutional investors
December 6, 2019
Sage Therapeutics' (SAGE) depression (MDD) drug fails in clinical trial missing endpoint, stock price gets its clock cleaned
November 3, 2019
RegMed Investors’ (RMi): Ready, aim, clear the estimates and forecast firing range, earnings release are set to light-up and down size the sector
September 11, 2019
Remember and never forget!
August 19, 2019
Bellicum Pharmaceuticals (BLCM) prices 575 K preferred stock share and warrant offering at of $100.00
August 8, 2019
Stemline Therapeutics (STML) proposes 5 M share offering
August 5, 2019
Regenerative Medicine Earnings Scorecard - Q2/19 - to date
August 5, 2019
RegMed Investors’ (RMi): Worried about Q2 results, think six (6) market factors…
May 19, 2019
Regenerative Medicine Earnings Scorecard - Q1/19 - to date
April 8, 2019
Histogenics (HSGX) reverse mergers with Ocugen, Inc.
March 31, 2019
Regenerative Medicine Earnings Scorecard - Q4/18 and FY18 - to date
March 19, 2019
Sage Therapeutics (SAGE) gets FDA approval for Zulresso, a postpartum depression (severe depression after childbirth) therapy
March 12, 2019
Osiris Therapeutics to be acquired for $660 M or +$19 per share by Smith & Nephew
March 11, 2019
BioTime (NYSE American: BTX) closes acquisition of Asterias Biotherapeutics (NYSE American: AST)
February 26, 2019
Ultragenyx Pharmaceutical (RARE) prices a 5.072 M share offering at $60.00
8 hours 58 min ago
RegMed Investors’ (RMi) pre-open: Waiting the wait
My motto … never leave an investor uninformed! I say today what others won’t, so you can do what others can’t.
My name is Henry McCusker; I endorse these opinions under my own name and with a subscription based membership.
Do you have an opinion you would like to share with us? We would like to hear from you.
Please e-mail us at hwm@regmedinvestors.com.
Editor and Publisher ... Henry McCusker enters his tenth (10th) year at RegMed Investors
© 2025 RegMed Investors (regmedinvestors.com), all rights are reserved.
RegMed Investors (RMi) or Regmedinvestors.com content is the intellectual property of Henry McCusker. Any copying, republication or redistribution of RMI’s content, including by framing or similar means, is expressly prohibited without the prior written consent of Scimitar; who also shall not be liable for any errors or delays in content, or for any actions taken in reliance thereon. For additional information on other Scimitar media services or reposting please email hwm@regmedinvestors.com.
The information included above as well as individual companies and/or securities mentioned should be construed as guidance in RMi reviews.
The facts stated and the opinions given in this publication are based on data and information considered to be reliable and have been carefully worked into my qualitative analyses and prognoses. However, no guarantee can be given as to their fairness, accuracy or completeness.
Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.